Stockreport

Kazia Therapeutics Expands Oncology Platform with First-in-Class SETDB1 Inhibitor Drug Development Platform [TheStreet.com]

Kazia Therapeutics Limited - American Depositary Shares  (KZIA) 
US:NASDAQ Investor Relations: kaziatherapeutics.com
PDF SYDNEY, Australia April 13, 2026 /PRNewswire/ -- Kazia Therapeutics Limited (Nasdaq: KZIA), a clinical-stage oncology company advancing therapies to reprogram cancer bi [Read more]